Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Myeloproliferative Neoplasms Specialty Channel

Myeloproliferative Neoplasms
Specialty Channel
News
03/18/2024

Jordan Kadish

Jordan Kadish
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR...
03/18/2024
Oncology
Anthony Hunter, MD
Videos
10/16/2023
Anthony Hunter, MD, discusses the role of interferon regimens for patients with myeloproliferative neoplasms, including polycythemia vera and essential thrombocythemia.
Anthony Hunter, MD, discusses the role of interferon regimens for patients with myeloproliferative neoplasms, including polycythemia vera and essential thrombocythemia.
Anthony Hunter, MD, discusses...
10/16/2023
Oncology
Quiz
09/25/2023
True or False: Results of a retrospective, real-world analysis determined that some patients with chronic myeloproliferative neoplasm polycythemia vera received underdosed hydroxyurea, which led to lower complete response and toxicity rates,...
True or False: Results of a retrospective, real-world analysis determined that some patients with chronic myeloproliferative neoplasm polycythemia vera received underdosed hydroxyurea, which led to lower complete response and toxicity rates,...
True or False: Results of a...
09/25/2023
Oncology
News
08/22/2023
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio...
08/22/2023
Oncology
News
08/09/2023
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea...
08/09/2023
Oncology
News
07/14/2023
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of...
07/14/2023
Oncology
News
05/05/2023
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to...
05/05/2023
Oncology
John Mascarenhas, MD
Videos
05/04/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies conference, New York, John Mascarenhas, MD, discussed recent advancements in clinical developments for the treatment of myeloproliferative neoplasms, specifically myelofibrosis,...
At the 2023 Great Debates & Updates in Hematologic Malignancies conference, New York, John Mascarenhas, MD, discussed recent advancements in clinical developments for the treatment of myeloproliferative neoplasms, specifically myelofibrosis,...
At the 2023 Great Debates &...
05/04/2023
Oncology
Claire Harrison, MD
Videos
05/04/2023
In the final part of an expert roundtable series, Claire Harrison, MD, leads a panel discussion reviewing data on second-line therapies, particularly ruxolitinib, for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and...
In the final part of an expert roundtable series, Claire Harrison, MD, leads a panel discussion reviewing data on second-line therapies, particularly ruxolitinib, for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and...
In the final part of an expert...
05/04/2023
Oncology
Claire Harrison, MD
Videos
05/04/2023
In part 3 of an expert roundtable series, Claire Harrison, MD, leads a panel discussion on how to determine when first-line polycythemia vera therapy is failing with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 3 of an expert roundtable series, Claire Harrison, MD, leads a panel discussion on how to determine when first-line polycythemia vera therapy is failing with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 3 of an expert...
05/04/2023
Oncology
Claire Harrison, MD
Videos
05/04/2023
In part 2 of an expert roundtable series, Claire Harrison, MD, leads a discussion on the aims of treatment and choice of first-line therapy for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 2 of an expert roundtable series, Claire Harrison, MD, leads a discussion on the aims of treatment and choice of first-line therapy for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 2 of an expert...
05/04/2023
Oncology

Advertisement

News

News
03/18/2024

Jordan Kadish

Jordan Kadish
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR...
03/18/2024
Oncology
News
08/22/2023
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio...
08/22/2023
Oncology
News
08/09/2023
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea...
08/09/2023
Oncology
News
07/14/2023
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of...
07/14/2023
Oncology
News
05/05/2023
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to...
05/05/2023
Oncology
News
04/21/2023
According to a phase 3 trial, momelotinib, a first-class JAK1 and JAK2 inhibitor, improved anemia measures, spleen response, and overall safety among patients with myelofibrosis compared to other JAK inhibitors.
According to a phase 3 trial, momelotinib, a first-class JAK1 and JAK2 inhibitor, improved anemia measures, spleen response, and overall safety among patients with myelofibrosis compared to other JAK inhibitors.
According to a phase 3 trial,...
04/21/2023
Oncology
News
03/13/2023
Low-intensity regimens for sickle cell disease transplantations were associated with a higher risk of secondary neoplasms, including leukemia and myelodysplastic syndromes.
Low-intensity regimens for sickle cell disease transplantations were associated with a higher risk of secondary neoplasms, including leukemia and myelodysplastic syndromes.
Low-intensity regimens for...
03/13/2023
Oncology
Conference Coverage
02/27/2023
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that...
02/27/2023
Oncology
News
02/27/2023
A study found that patients with non-proliferative CBC thrombosis MPNs and driver mutations with non-splanchnic involvement have an increased risk for recurrent blood clots and progression of the disorder than those with splanchnic...
A study found that patients with non-proliferative CBC thrombosis MPNs and driver mutations with non-splanchnic involvement have an increased risk for recurrent blood clots and progression of the disorder than those with splanchnic...
A study found that patients with...
02/27/2023
Oncology
News
09/30/2022
Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombotic events in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombotic events in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
Both conventional cytoreduction...
09/30/2022
Oncology

Interactive Features

Quiz
09/25/2023
True or False: Results of a retrospective, real-world analysis determined that some patients with chronic myeloproliferative neoplasm polycythemia vera received underdosed hydroxyurea, which led to lower complete response and toxicity rates,...
True or False: Results of a retrospective, real-world analysis determined that some patients with chronic myeloproliferative neoplasm polycythemia vera received underdosed hydroxyurea, which led to lower complete response and toxicity rates,...
True or False: Results of a...
09/25/2023
Oncology
Quiz
11/30/2022
True or False: Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
True or False: Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
True or False: Both conventional...
11/30/2022
Oncology
Quiz
09/02/2022
The FDA granted approval to pemigatinib to treat adult patients with relapsed or refractory myeloid/lymphoid neoplasms and an FGFR1 rearrangement. In the phase 2 trial which led to the approval, what was the complete cytogenetic response rate...
The FDA granted approval to pemigatinib to treat adult patients with relapsed or refractory myeloid/lymphoid neoplasms and an FGFR1 rearrangement. In the phase 2 trial which led to the approval, what was the complete cytogenetic response rate...
The FDA granted approval to...
09/02/2022
Oncology
idea
Test Your Knowledge
02/01/2022
True or false: A retrospective study found antiplatelet and anticoagulation therapies do not increase the risk of bleeding events in patients with MPNs.
True or false: A retrospective study found antiplatelet and anticoagulation therapies do not increase the risk of bleeding events in patients with MPNs.
True or false: A retrospective...
02/01/2022
Oncology
Question marks
Quiz
01/20/2022
True or false: A phase 2 study found sotatercept to be unsafe and ineffective for anemic patients with MPN-associated MF.
True or false: A phase 2 study found sotatercept to be unsafe and ineffective for anemic patients with MPN-associated MF.
True or false: A phase 2 study...
01/20/2022
Oncology
writing
Test Your Knowledge
01/06/2022
True or false: Findings from a single-center retrospective study investigated the prognostic implication of pulmonary hypertension (PH) in a high-risk MPNs patient population and found PH is associated with worse outcomes.
True or false: Findings from a single-center retrospective study investigated the prognostic implication of pulmonary hypertension (PH) in a high-risk MPNs patient population and found PH is associated with worse outcomes.
True or false: Findings from a...
01/06/2022
Oncology
?
Test Your Knowledge
12/17/2021
True or false: DOAC’s are associated with high bleeding rates in patients with MPNs.
True or false: DOAC’s are associated with high bleeding rates in patients with MPNs.
True or false: DOAC’s are...
12/17/2021
Oncology
Computer
Test Your Knowledge
12/16/2021
True or false: JAK inhibitor therapy is safe and effective in patients with MPNs complicated by PT without underlying ST.
True or false: JAK inhibitor therapy is safe and effective in patients with MPNs complicated by PT without underlying ST.
True or false: JAK inhibitor...
12/16/2021
Oncology
Test Your Knowledge
11/29/2021
Which of the following mutations is associated with a higher risk of bleeding in adult patients with MPN?
Which of the following mutations is associated with a higher risk of bleeding in adult patients with MPN?
Which of the following mutations...
11/29/2021
Oncology
qq
Test Your Knowledge
11/11/2021
Which of the following mutations was identified as a high-risk bleeding factor in MPN?
Which of the following mutations was identified as a high-risk bleeding factor in MPN?
Which of the following mutations...
11/11/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement